Abstract
Recent studies have shown that matrix metalloproteinases (MMPs) might be a biomarker for predicting outcomes of bladder cancer. However, the prognostic value of overexpression of MMPs in bladder cancer is debatable and the studies are inconsistent. Therefore, this meta-analysis was performed to clarify the specific association and prognostic value of overexpression of MMPs in bladder carcinoma. Relevant studies were identified by searching PubMed, EMBASE, and the Web of Science. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for disease-specific survival (DSS), overall survival (OS), disease/recurrence-free survival (DFS/RFS), and progression/metastasis-free survival (PFS/MFS) were analyzed to determine the prognostic value of MMPs. In total, eighteen applicable studies were included in this meta-analysis. We found that high expression of MMPs significantly correlated with a poor DSS and OS (HR=1.66; 95% CI = 1.38–2.01 and HR= 1.67; 95%CI= 1.26–2.22). MMPs also predicted tumor progression and metastasis with a pooled HR of 3.03 (95% CI 1.98–4.64). However, high MMPs expression had no pivotal impact on DFS/RFS (HR= 1.21; 95% CI= 0.96–1.53). With the purpose of better understanding the prognostic role of MMPs in patients wirh bladder carcinoma, we carried out this systematic review and meta-analysis.
Highlights
Despite a declining occurrence rate in recent years, bladder cancer is still the most frequent malignancy of the urinary system worldwide
We found that high expression of matrix metalloproteinases (MMPs) significantly correlated with a poor diseasespecific survival (DSS) and overall survival (OS) (HR=1.66; 95% confidence intervals (CIs) = 1.38–2.01 and hazard ratios (HRs)= 1.67; 95%CI= 1.26–2.22)
With the purpose of better understanding the prognostic role of MMPs in patients wirh bladder carcinoma, we carried out this systematic review and meta-analysis
Summary
Despite a declining occurrence rate in recent years, bladder cancer is still the most frequent malignancy of the urinary system worldwide. 386, 000 new cases of bladder carcinoma and 150, 000 disease-specific deaths occur worldwide every year [2]. Some progress has been made in therapeutic approaches for bladder cancer, patients still experienced poor survival outcome, with high recurrence and mortality. The pathogenesis and progression of bladder cancer is complicated, and its occurrence and development seem to be influenced by many factors, such as multiple genes and external environmental factors [5, 6]. To improve the quality of patients’ individual care, it is essential to investigate prognostic factors for survival and recurrence of bladder cancer and identify novel techniques for diagnosis and treatment [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
